What should I do if I develop drug resistance after taking acalatinib/acalatinib?

Acalabrutinib (Acalabrutinib), or ACP-196, is an advanced, irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor. It exhibits higher efficacy and selectivity than ibrutinib by blocking the activation of the B cell antigen receptor (BCR) signaling pathway. After in-depth clinical trials, the drug has been widely used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma and mantle cell lymphoma.

Although acotinib has improved efficacy and selectivity compared to ibrutinib, some patients still develop drug resistance. A recent study revealed the emergence of drug resistance in CLL patients treated with acotinib. For acotinib resistance, the following strategies and methods are worth considering:

The first step is to confirm whether the patient is indeed resistant to acotinib through detailed testing and analysis, and to explore the reasons behind it, such as mutations in specific genes. In some cases, resistance may be due to insufficient drug concentrations in the patient's body. In response to this situation, you can consider increasing the dose of acotinib appropriately to increase its concentration in the body, thereby better inhibiting the growth of cancer cells.

If acotinib alone cannot effectively control drug-resistant disease, it may be considered in combination with other treatments. For example, acotinib may be used with chemotherapy drugs or immunotherapy to enhance the overall effectiveness of the treatment. When resistance develops, a completely new treatment regimen may need to be considered. New regimens can choose other drugs that target specific cell signaling pathways, or other types of chemotherapy drugs, in order to attack cancer cells through different mechanisms of action and reduce the development of drug resistance.

In summary, in the face of acotinib resistance, we need to develop reasonable response strategies based on the specific conditions of the patients. By identifying the resistance mechanism early and taking corresponding measures, we can effectively improve the treatment effect and extend the patient's survival. At the same time, active participation in clinical trials can also bring more treatment possibilities to drug-resistant patients.